Uniplan Investment Counsel’s iRadimed IRMD Stock Holding History

Uniplan Investment Counsel’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.98M	Sell	62,141 -3,554	-5%	-$355K	0.61%	44
2025 Q4	$6.39M	Sell	65,695 -11,619	-15%	-$997K	0.64%	42
2025 Q3	$5.5M	Sell	77,314 -3,033	-4%	-$202K	0.54%	48
2025 Q2	$4.8M	Buy	80,347 +31,620	+65%	+$1.73M	0.49%	54
2025 Q1	$2.56M	Buy	48,727 +16,187	+50%	+$909K	0.25%	95
2024 Q4	$1.79M	Buy	+32,540	New	+$1.71M	0.17%	106

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Uniplan Investment Counsel's IRMD Position: Q1 2026 in Review

Uniplan Investment Counsel reduced its iRadimed (IRMD) stake by 5.4% in Q1 2026, selling an estimated $355K and leaving 62,141 shares worth $5.98M. The position accounts for 0.61% of the portfolio, ranked #44.

Uniplan Investment Counsel first reported a position in IRMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.39M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

Uniplan Investment Counsel held 62,141 shares of iRadimed worth $5.98M as of Q1 2026.
Uniplan Investment Counsel sold 3,554 iRadimed shares in Q1 2026, an estimated $355K.
iRadimed made up 0.61% of Uniplan Investment Counsel's portfolio in Q1 2026, its #44 holding.
Uniplan Investment Counsel first reported a position in iRadimed in Q4 2024 and has held it in 6 quarters since.
Uniplan Investment Counsel's iRadimed position peaked at $6.39M in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Uniplan Investment Counsel's 13F filing for Q1 2026, filed 15 May 2026.